Outcomes of Allogeneic Stem Cell Transplantation in a North American Adult T Cell Leukemia/Lymphoma Cohort.
We aimed to evaluate post-HCT survival, toxicities, and prognostic risk factors in NA-ATLL. These data suggest that fit patients should proceed to HCT expeditiously with any donor option available.
We aimed to evaluate post-HCT survival, toxicities, and prognostic risk factors in NA-ATLL. These data suggest that fit patients should proceed to HCT expeditiously with any donor option available.
What the study was
- Study design
- Retrospective observational study
- Population
- Human participants; details are provided in the abstract.
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Transplantation and cellular therapy
Why it surfaced
Retained as a 8/10 high-priority candidate for Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma); PubMed metadata and abstract were assessed conservatively.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.